Analyst consensus rating

TScan Therapeutics Analyst Rating: Hold

Direct answer

TScan Therapeutics's consensus rating is Hold.

1 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $1.00.
Forecast evidence checked November 21, 2026.

Get free TScan Therapeutics email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Current price
$0.15
Average price target
$1.00
High price target
$1.00
Low price target
$1.00
Low target gap
+585.4%
Target upside
+585.4%
High target gap
+585.4%
Target range width
0%
Consensus rating
Hold
Analysts
1
Evidence date
November 21, 2026
Valid through
November 28, 2026

Read the frequently asked questions.

What is the analyst consensus rating for TScan Therapeutics?

TScan Therapeutics has a verified Hold consensus. The same dataset has an average price target of $1.00.

How far are TScan Therapeutics's low and high targets from the recorded price?

The low target implies +585.4%, while the high target implies +585.4%.

How many analysts are included in TScan Therapeutics's consensus?

The verified consensus includes 1 analysts.

How is TScan Therapeutics's target upside or downside calculated?

The average target of $1.00 is divided by the recorded price of $0.15, then one is subtracted to produce +585.4%. This does not guarantee a future return.

When was TScan Therapeutics's analyst forecast verified?

The data was verified on 2026-11-21. The dataset is valid through 2026-11-28.